Core Viewpoint - The company, Haohai Biological Technology, reported a decline in revenue and net profit for the fiscal year 2025, indicating significant operational challenges in the artificial lens market due to increased competition and changing market dynamics [1][2]. Group 1: Financial Performance - Total revenue for 2025 was approximately 2.473 billion yuan, a year-on-year decrease of 8.33% [1] - Net profit attributable to the parent company was about 251 million yuan, down 40.3% year-on-year [1] - Net profit excluding non-recurring gains and losses was approximately 160 million yuan, reflecting a 57.67% decrease year-on-year [1] - Basic earnings per share stood at 1.08 yuan [1] Group 2: Market Conditions - The domestic cataract surgery volume in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [2] - Increased competition in the market, particularly from domestic lens products that offer significant cost and price advantages over imported brands, is putting pressure on sales [2] - Sales prices and volumes of the Lenstec brand artificial lenses are experiencing a continuous downward trend in 2025 [2] Group 3: Impairment Provisions - The company has made a prudent decision to recognize an impairment provision of approximately 140 million yuan for goodwill related to its subsidiary Shenzhen New Industry due to underperformance [2] - The impairment amount is subject to final assessment and audit by qualified evaluation and auditing institutions [2] - Additionally, the company recognized an impairment provision of about 24.98 million yuan for intangible assets related to its U.S. subsidiary Aaren Scientific Inc. due to signs of impairment [3]
昊海生物科技2025年归母净利约2.51亿元，同比减少40.3%